Lilly, Nektar to co-develop new immunotherapy – PharmaTimes
PharmaTimes |
Lilly, Nektar to co-develop new immunotherapy
PharmaTimes Eli Lilly and Nektar Therapeutics have signed a pact to co-develop the latter’s experimental immunotherapy NKTR-358 for a range of autoimmune and other chronic inflammatory conditions under a deal valued at $400 million. NKTR-358 is a potential … Nektar Therapeutics – NKTR – Stock Price Today – ZacksZacks Investment Research |
|
Health Shorts: Stem cell ‘cures,’ Sugar spike, Longevity
Sarasota Herald-Tribune Stem cell clinics offering unapproved treatments for ailments from hip pains to erectile dysfunction increasingly use a federal clinical-trials database as a marketing tool — a strategy that confuses patients and exposes them to “unjustifiable” safety … |
|
Cellectis wins European patent for CRISPR use in T-cells
News-Medical.net “We have been the first to explore the potential of CRISPR in its early days in various applications, including therapeutics and food, and these early findings ultimately led to the grant of this new patent. While Cellectis has selected TALEN® as the … |
